Dr Reddy's gets FDA nod for generic Revlimid; enjoys 180 days exclusivity

​​"We are pleased with the Agency's approval of Lenalidomide Capsules, 2.5 mg and 20 mg and being eligible for 180-day market exclusivity. We look forward to bringing a more affordable generic version of this drug to market for the benefit of patients," Marc Kikuchi, CEO, North America Generics, Dr. Reddy's Laboratories said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3G1JGIo
via IFTTT